WO2000004141A3 - Use of nucleic acid molecules as antiviral agents - Google Patents

Use of nucleic acid molecules as antiviral agents Download PDF

Info

Publication number
WO2000004141A3
WO2000004141A3 PCT/US1999/016253 US9916253W WO0004141A3 WO 2000004141 A3 WO2000004141 A3 WO 2000004141A3 US 9916253 W US9916253 W US 9916253W WO 0004141 A3 WO0004141 A3 WO 0004141A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
antiviral agents
viral polymerase
inhibiting
Prior art date
Application number
PCT/US1999/016253
Other languages
French (fr)
Other versions
WO2000004141A2 (en
Inventor
Cheng C Kao
Robert W Siegel
Laurent Bellon
Leonid Beigelman
Original Assignee
Ribozyme Pharm Inc
Advanced Res & Tech Inst
Cheng C Kao
Robert W Siegel
Laurent Bellon
Leonid Beigelman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc, Advanced Res & Tech Inst, Cheng C Kao, Robert W Siegel, Laurent Bellon, Leonid Beigelman filed Critical Ribozyme Pharm Inc
Priority to AU53169/99A priority Critical patent/AU5316999A/en
Priority to CA002334161A priority patent/CA2334161A1/en
Priority to EP99938756A priority patent/EP1098969A2/en
Priority to JP2000560239A priority patent/JP2002520051A/en
Publication of WO2000004141A2 publication Critical patent/WO2000004141A2/en
Publication of WO2000004141A3 publication Critical patent/WO2000004141A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A linear single stranded nucleic acid molecule capable of specifically binding to a viral polymerase and inhibiting the activity of said viral polymerase.
PCT/US1999/016253 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents WO2000004141A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU53169/99A AU5316999A (en) 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents
CA002334161A CA2334161A1 (en) 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents
EP99938756A EP1098969A2 (en) 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents
JP2000560239A JP2002520051A (en) 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9348998P 1998-07-20 1998-07-20
US17951698A 1998-10-26 1998-10-26
US60/093,489 1998-10-26
US09/179,516 1998-10-26

Publications (2)

Publication Number Publication Date
WO2000004141A2 WO2000004141A2 (en) 2000-01-27
WO2000004141A3 true WO2000004141A3 (en) 2000-04-27

Family

ID=26787599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016253 WO2000004141A2 (en) 1998-07-20 1999-07-15 Use of nucleic acid molecules as antiviral agents

Country Status (5)

Country Link
EP (1) EP1098969A2 (en)
JP (1) JP2002520051A (en)
AU (1) AU5316999A (en)
CA (1) CA2334161A1 (en)
WO (1) WO2000004141A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294457B2 (en) * 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ES2322602T3 (en) 2004-02-24 2009-06-23 Japan Tobacco, Inc. CONDENSED HETEROTETHYCLIC COMPOUNDS AND ITS USE AS AN HCV POLYMERASE INHIBITOR.
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010328A2 (en) * 1995-07-13 1997-03-20 Ribozyme Pharmaceuticals, Inc. Compositions and method for modulation of gene expression in plants
WO1997026270A2 (en) * 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
WO1998003668A1 (en) * 1996-07-22 1998-01-29 Zeneca Limited Virus resistance in plants
WO1999049031A1 (en) * 1998-03-26 1999-09-30 Advanced Research And Technology Institute, Inc. Use of nucleic acid molecules as antiviral agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010328A2 (en) * 1995-07-13 1997-03-20 Ribozyme Pharmaceuticals, Inc. Compositions and method for modulation of gene expression in plants
WO1997026270A2 (en) * 1996-01-16 1997-07-24 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
WO1998003668A1 (en) * 1996-07-22 1998-01-29 Zeneca Limited Virus resistance in plants
WO1999049031A1 (en) * 1998-03-26 1999-09-30 Advanced Research And Technology Institute, Inc. Use of nucleic acid molecules as antiviral agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADKINS S ET AL: "Minimal templates directing accurate initiation of subgenomic RNA synthesis in vitro by the brome mosaic virus RNA-dependent RNA polymerase.", RNA, (1997 JUN) 3 (6) 634-47., XP002110077 *
ADKINS S ET AL: "Subgenomic RNA promoters dictate the mode of recognition by bromoviral RNA-dependent RNA polymerases.", VIROLOGY, (1998 DEC 5) 252 (1) 1-8., XP002110079 *
HUNTLEY C C ET AL: "MINUS SENSE TRANSCRIPTS OF BROME MOSAIC VIRUS RNA-3 INTERCISTRONIC REGION INTERFERE WITH VIRAL REPLICATION", VIROLOGY, vol. 192, 1993, pages 290 - 297, XP002047298, ISSN: 0042-6822 *
SIEGEL, R. ET AL.: "Moieties in an RNA promoter specifically recognized by a viral RNA-dependent RNA polymerase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, September 1998 (1998-09-01), pages 11613 - 11618, XP002110078, ISSN: 0027-8424 *
SIEGEL, R. ET AL.: "Sequence-specific recognition of a subgenomic RNA promoter by a viral RNA polymerase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, October 1997 (1997-10-01), pages 11238 - 11243, XP002110076, ISSN: 0027-8424 *
ZACCOMER B ET AL: "TRANSGENIC PLANTS THAT EXPRESS GENES INCLUDING THE 3' UNTRANSLATED REGION OF THE TURNIP YELLOW MOSAIC VIRUS (TYMV) GENOME ARE PARTIALLY PROTECTED AGAINST TYMV INFECTION", GENE, vol. 136, 1 January 1993 (1993-01-01), pages 87 - 94, XP002047299, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2000004141A2 (en) 2000-01-27
CA2334161A1 (en) 2000-01-27
EP1098969A2 (en) 2001-05-16
JP2002520051A (en) 2002-07-09
AU5316999A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
ZA981762B (en) Nucleic acid molecules encoding enzymes having fructosyl polymerase activity.
AU3719700A (en) Enzymatic dna molecules that contain modified nucleotides
AU4332399A (en) Rna polymerase chain reaction
AU4567499A (en) Novel mtbx protein and nucleic acid molecules and uses therefor
AU6589094A (en) 7-deazapurine modified oligonucleotides
AU3199699A (en) Modified nucleotides and methods useful for nucleic acid sequencing
AU2001268513A1 (en) Nucleic acid accessible hybridization sites
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
WO2002004488A3 (en) Nucleic acid binding polypeptides
AU3666097A (en) Novel catalytic rna molecules
EP1144682A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU5916399A (en) Nucleic acid ligand interaction assays
DE69833112D1 (en) Rna polymerase
WO2000004141A3 (en) Use of nucleic acid molecules as antiviral agents
AU1941601A (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
ZA200101737B (en) Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof.
EP1058737A4 (en) Novel fdrg protein and nucleic acid molecules and uses therefor
AU7309500A (en) Metal cluster containing nucleotides and nucleic acids, and intermediates therefor
EP1071749A4 (en) Novel lrsg protein and nucleic acid molecules and uses therefor
AU6376698A (en) Improved nucleic acid assays
GB2344591B (en) Thermostable DNA polymerase
AU3210199A (en) Use of nucleic acid molecules as antiviral agents
EP1090997A4 (en) Hcv-derived rna polymerase gene
EP1007682A4 (en) Novel nucleic acid molecules and uses therefor
AU3586101A (en) Dna polymerase mu and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2334161

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999938756

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 560239

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999938756

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999938756

Country of ref document: EP